Frederick L. Locke, MD
Frederick L. Locke, MD, is chair, Department of Blood and Marrow Transplant and Cellular Immunotherapy, and a medical oncologist and translational researcher who treats lymphoma and multiple myeloma at Moffitt Cancer Center in Tampa, Florida. He also conducts clinical trials of CAR T-cell therapy for patients with lymphoma and myeloma.
Articles
Cema-Cel Data Highlight Potential in Allogeneic CAR T: Fred Locke, MD
In part 4 of an interview with The American Journal of Managed Care®, Frederick L. Locke, MD, provides insight on the design of the ALPHA and ALPHA2 trials, which are investigating the chimeric antigen receptor T-cell therapy (CAR T) cemacabtagene ansegedleucel (cema-cel) in relapsed/refractory large B-cell lymphoma.
Allogeneic vs Autologous CAR T-Cell Therapy Explained
On February 13, Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative allogeneic chimeric antigen receptor (CAR) T-cell therapy produced durable responses in relapsed/refractory large B-cell lymphoma.
